ArticleClinical lymphoma, myeloma & leukemia2022

Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.

Marina Moretti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.